World Pharma Today: Powering Through Into 2025 With A Strong Foundation

World Pharma Today, in its advent to be the standalone ready-reckoner in the pharma domain, is proud to present expert predictions for 2025 from leading voices in the pharmaceutical industry. From groundbreaking advancements in bioconjugates and cell and gene therapies to the integration of digital solutions and innovative device technologies, these insights reveal the trends shaping the future of pharma and healthcare. Key themes include supply chain efficiency, patient-centric solutions, platform standardization, and leveraging data-driven approaches for accelerated drug development. Stay informed with thought leadership from industry pioneers like Abzena, TrakCel, Recipharm, Renaissance Lakewood and Simbec-Orion as we explore the evolving landscape of pharma innovation.

We begin with Abzena, which talks about going beyond the regular antibody-drug conjugations (ADCs). Then we move to a piece from TrakCel that lays focus on increased productivity and efficiency across advanced therapy supply chains. Recipharm then shows the significance of digital solutions so as to pass through the intricacies of drug development. Renaissance Lakewood, thereafter, gives a brief on the advancement in the nasal spray device tech. Finally, we put the spotlight on Simbec-Orion that talks specifically on Project Optimus designed due to the rising number of molecularly targeted oncology therapies which are in development.

Essentially, we talk of what all these 5 companies saw as the biggest trend in their respective domains and if they foresee this to continue in 2025 as well, thereby not just aligning to their respective goals but also witnessing immense promise throughout each of them.

Abzena

Author: Campbell Bunce, Chief Scientific Officer

2024 marked the shift to complex modalities with bi and tri-specific antibodies being conjugated to a wide variety of payloads from cytotoxics to nucleotides. With innovative options for more precise targeting and different payloads, there’s been an explosion in thinking of where and how these new bespoke conjugated molecules can be applied. Pharma has moved past simple Antibody-drug conjugations (ADCs), which have proven the approach but have surfaced some issues with clinical safety and complex manufacturing controls (CMC).

As we move into 2025 and developers apply more learnings from the first phase of bioconjugates, upfront de-risking of development and manufacturing is a must to support both early scientific and longer-term commercial success. By taking a toolbox of proven conjugation technologies, well understood biology and chemistry simplified with a platform approach, along with complementary analytical capabilities, will allow focus of expertise and resources on the novel value-add areas.

I believe 2025 will also see a burgeoning demand for standalone analytical capabilities as the impacts of the Biosecure Act and import tariffs on industry-wide complex supply chains play out. A holistic approach for development, characterization and commercial manufacturing will be vital to achieve the full therapeutic potential of these new technically challenging modalities.

Read The Full Article